缬沙坦联合他汀类药物治疗冠心病的价值
The value of valsartan combined with statins in the treatment of coronary heart disease
ES评分 0
| DOI |
10.12208/j.ijcr.20220458 |
| 刊名 |
International Journal of Clinical Research
|
| 年，卷(期) |
2022, 6(9) |
| 作者 |
|
| 作者单位 |
桐乡市梧桐街道社区卫生服务中心 浙江桐乡 ;
|
| 摘要 |
分析冠心病中缬沙坦联合他汀类药物治疗的干预效果。方法 选择近2年（2020年1月-2022年2月）本院门诊就诊的冠心病患者80例，回顾临床资料，将采用缬沙坦联合他汀类药物治疗的40例作为观察组，采用常规治疗的40例患者作为对照组，对比两组临床疗效。结果 观察组患者血脂水平改善情况明显更优，心功能指标改善情况更优，同时不良反应率更低，与对照组相比差异有统计学意义（P<0.05）。结论 缬沙坦联合他汀类药物治疗冠心病的效果良好，可有效调节血脂水平，改善患者心功能，不良反应状况发生少，为治疗该疾病提供了一定的治疗依据，临床应用价值确切。
|
| Abstract |
Objectives: To analyze the intervention effect of valsartan combined with statins in coronary heart disease. Methods: 80 patients with coronary heart disease admitted to our hospital in recent 2 years (January 2020 February 2022) were selected. The clinical data were reviewed. 40 patients treated with valsartan combined with statins were taken as the observation group, and 40 patients treated with conventional therapy were taken as the control group. The clinical effects of the two groups were compared. Results: Compared with the control group, the improvement of blood lipid level and cardiac function indicators in the observation group was significantly better, and the adverse reaction rate was lower (P<0.05). Conclusion: Valsartan combined with statins has a good effect in the treatment of coronary heart disease. It can effectively regulate the level of blood lipids, improve the heart function of patients, and has less adverse reactions. It provides a certain basis for the treatment of this disease, and has definite clinical application value.
|
| 关键词 |
冠心病；缬沙坦；他汀类药物；血脂水平；心功能；不良反应；效果
|
| KeyWord |
Coronary heart disease; Valsartan; Statins; Blood lipid level; Cardiac function; Adverse reactions; effect
|
| 基金项目 |
|
| 页码 |
159-161 |
王思雨*.
缬沙坦联合他汀类药物治疗冠心病的价值 [J].
国际临床研究杂志.
2022; 6; (9).
159 - 161.